ClinicalTrials.Veeva

Menu

Developing Trustworthy Artificial Intelligence (AI)-Driven Tools to Predict Vascular Disease Risk and Progression (VASCULAIDRETRO)

A

Amsterdam UMC, location VUmc

Status

Enrolling

Conditions

Aneurysm Abdominal
Peripheral Arterial Disease

Treatments

Other: No intervention, retrospective study

Study type

Observational

Funder types

Other

Identifiers

NCT06206369
2011279

Details and patient eligibility

About

The VASCULAID-RETRO study, within the broader VASCULAID project, aims to create artificial intelligence (AI) algorithms that can predict cardiovascular events and the progression of abdominal aortic aneurysm (AAA) and peripheral arterial disease (PAD). The study plans to gather and analyze data from at least 5000 AAA and 6000 PAD patients, combining existing cohorts and retrospectively collected data. During this project, AI tools will be developed to perform automatic anatomical segmentation and analyses on multimodal imaging. AI prediction algorithms will be developed based on multisource data (imaging, medical history, -omics).

Full description

To date, it is unknown which abdominal aortic aneurysm (AAA) and peripheral arterial disease (PAD) patients will suffer cardiovascular events or in which patients the AAA or PAD will progress. In the VASCULAID project, the VASCULAID-RETRO study aims to leverage data from existing cohorts and retrospectively collected data to develop artificial intelligence (AI) algorithms able to evaluate the risk of cardiovascular events and extent of disease progression.

In order to build and train the algorithms for the predictions, we plan to retrospectively enroll at least 5000 AAA and 6000 PAD patients AI-tools will be applied to the patient data. Automatic anatomical segmentation on images and image analysis on US, CTA and MRI will be performed. Also, algorithms to predict cardiovascular events and AAA or PAD progression based on multi-source data analysis will be developed.

Patient data from European clinical consortium partners is available. This consortium has access to big cohorts with relevant data for the envisioned study that will be used to enrich the existing registries. These data will be used to refine the algorithms developed for the prediction of cardiovascular events and AAA/PAD progression.

Enrollment

11,000 estimated patients

Sex

All

Ages

40 to 90 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Males and females, 40-90 years old, with an AAA >3cm. This includes patients with infrarenal, juxtarenal, suprarenal, iliac (defined as 1.5x its normal diameter) aneurysms, as well as mycotic aneurysms. Patients that have had interventions or ruptures will also be included
  • Males and females, 40-90 years old, all PAD patients (Fontaine stages 1,2,3, and 4).

Exclusion criteria

  • Patients with an ascending, thoracic, thoracoabdominal (type 1-3) aneurysm.

Trial design

11,000 participants in 2 patient groups

Abdominal Aortic Aneurysm patients
Treatment:
Other: No intervention, retrospective study
Peripheral Arterial Disease patients
Treatment:
Other: No intervention, retrospective study

Trial contacts and locations

6

Loading...

Central trial contact

Kak Khee Yeung, MD, PhD; Lotte Rijken, Msc.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems